THERAPY DOSSIER · th-d801e5e151b5

E-64-d (with methylprednisolone as a comparator and combination partner)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26240815 ↗2015Reported benefit

Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury.

RatSpinal cord injuryContusionSprague DawleyMalen = Five groups (sham, SCI, E-64-d, methylprednisolone, E-64-d…IntravenousE-64-d 1 mg/kg in 1.5% DMSO vehicle; methylprednisolone 165…Immediately after injury

Model: Acute contusive spinal cord injury at T10 by laminectomy followed by modified Allen's weight-drop method (5 g weight dropped from 8 cm onto a 0.3 cm impounder)

E-64-d given immediately after injury reduced calpain 1 mRNA and protein, limited 68-kD NFP and MAP1B degradation, lowered caspase-3 activity and cytosolic AIF, reduced NeuN-TUNEL-positive neuronal apoptosis, reduced GFAP staining and COX-2 activity, and improved inclined plane angle and BBB scores…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…